Supplement Scholar
Neuropathy / Repair

ARA-290 (Cibinetide)

Research compound. This is not a dietary supplement. Unless it is identified as an approved prescription drug, it is not approved by the FDA for human use. This page summarizes published research for education only; we do not sell it or link to sellers.

ARA-290 (Cibinetide). 11-amino-acid peptide derived from erythropoietin that targets tissue repair without raising red blood cell counts.

How it works. Activates the innate repair receptor, a pairing of the EPO receptor with CD131, which dampens inflammation and supports nerve repair.

What the research supports. 2 graded claims. Strongest: Reduces neuropathic pain in sarcoidosis small-fiber neuropathy (limited).

Side effects and interactions. 0 medication interactions listed. Serious: Long-term safety not established.

Common forms. Available as Subcutaneous injection (trials).

Community. Experiences from people who have tried ARA-290 (Cibinetide). Anecdotes are not medical advice.

ARA-290 (Cibinetide). 11-amino-acid peptide derived from erythropoietin that targets tissue repair without raising red blood cell counts.

11-residue chainC51H84N16O21 · 1257.3 g/mol

What it is

Designed to keep EPO's tissue-protective effect while avoiding its blood-thickening effect. Small phase 2 trials in sarcoidosis-related small-fiber neuropathy and in diabetic neuropathy reported less pain and more small nerve fibers.

Also called

CibinetideHelix B surface peptide

How it works

Activates the innate repair receptor, a pairing of the EPO receptor with CD131, which dampens inflammation and supports nerve repair.

Pathways

  • Innate repair receptor (EPOR / CD131)
  • Anti-inflammatory signaling
  • Small-fiber nerve regeneration

Effects

  • ↓Neuropathic pain decreases
  • +Small nerve fiber regrowth supports
  • ↓Inflammation decreases

What the research supports

Reduces neuropathic pain in sarcoidosis small-fiber neuropathylimited
Increases corneal small nerve fiber densitylimited

Strong: consistent results across large trials or meta-analyses. Moderate: several trials, mostly positive. Limited: small or mixed studies. Preclinical: animal or cell research only.

Side effects & interactions

Common side effects

  • Injection-site reactions
  • Headache

Serious

  • Long-term safety not established

No notable medication interactions listed.

Check any supplement–medication combination with your pharmacist before starting.

Common forms

  • Subcutaneous injection (trials)

Discussion

Loading discussion…